Page 1 of 2

Anser Medical Sustainability Report

Purpose

The organization's Corporate Social Responsibility (CSR) policy emphasizes our commitment toward our people, the wider community and environment; the Sustainability Report provides detail on how going forward we will look to reduce our emissions to achieve net zero.

Scope

As an SME we are time and resource constrained concerning responding to the additional requirement around action being taken to reduce human caused climate change; however, the scope of the report includes two distinct sections concerning emissions reduction, the area in which:

- a. Anser Medical has control over and can implement plans.
- b. Suppliers have control over and Anser Medical needs to use persuasion to encourage emissions reduction.

What follows below describes the plans we must use to reduce our carbon footprint and influence our suppliers to do the same.

Authority & Responsibilities

Managing Director is to be responsible for compiling and publishing the report on the company website.

Methodology

As we focus on growing the company, our absolute carbon footprint is likely to grow with respect to our base line year (2022) Scope 1, 2 & 3 values. However, reporting Scope 1, 2 and 3 as intensities based on company turnover pa provides a metric of gCO_2e/\pounds which in the latest CRP containing 2023 reported data appears to be reducing.

As indicated in the Carbon Reduction Plan, the base year emissions under Scope 1 comprises 77%, Scope 2 13% and Scope 3 (without including purchased goods emissions) 10%.

i. Plans to Reduce Scope 1 Emissions:

The base year emissions comprised 62% due to the use of cars and fuel while doing business; 67% of this value was due to fuel, 37% of the total emissions.

If we could reduce our use of ICE vehicles, we would significantly reduce our total emissions.

Anser Medical Ltd 20-Feb-24

Title: Anser Medical Sustainability Report (AMSR)	No: 7.1.4-AMSR FY23-24 Page 2 of 2

Objective 1: As soon as financially able switch away from using ICE to EV vehicles.

ii. Plan to Reduce Scope 2 Emissions:

Although the electricity used comprises only 13% of the emissions, this is an easy area to potentially reduce to zero before 2030.

We have dismantled, repaired, and reconstructed a 1930's wooden building and are in the process of fitting out the refurbished interior to become the company's National Distribution Center. This new facility will shortly be open for use.

This new building will initially rely on mains electricity provided via the national grid. However, the long-term plan, as finances allow, comprises the following steps:

- 1. 1st April 2024, open the NDC and office complex supplied via mains power to run the air conditioning & heater unit. This will provide data concerning the base power consumption of the new facility.
- 2. 1st April 2025, obtain a ground source heat pump and connect to the already installed underfloor heating system.
- 3. 1st April 2026, obtain solar panels and storage batteries to generate and run the air conditioning and ground source heat pump.
- 4. 1st April 2027, obtain wind turbines to complement the solar panels as a local source of electricity.

Objective two by 2030: Run the NDC's power needs 24/7 365 days pa, technology allowing, off the mains grid i.e. all power required will be locally generated.

iii. Plan to Reduce Scope 3 Emissions

Our current Scope 3 emissions derive from upstream transport of our medical devices purchased from our suppliers base outside of the UK which constitutes 9% of the total emission, and downstream transport for delivery of stock to UK end users which comprises 1.5% of the total.

For upstream emissions we obtain figures from shipping firms and for downstream emissions we obtain figures from the Royal Mail who deliver >98% of our orders.

Missing from the Scope 3 figures is the carbon footprint to produce the medical devices we have shipped to the UK.

Objective three for 1st April 2025; engage with our suppliers to begin to obtain data concerning the Carbon Footprint for each device supplied in preparation for including in the CRP.

Anser Medical Ltd 20-Feb-24

Title: Anser Medical	Sustainability	y Report ((AMSR)
----------------------	----------------	------------	--------

No: 7.1.4-AMSR FY23-24

Page 3 of 2

Reviewed and verified by:	Managing Director
Date:	19 th February 2024

Anser Medical Ltd 20-Feb-24